Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06233942. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT06233942
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- BeOne Medicines
- Industry
- Enrollment
- 308 participants
Conditions and interventions
Conditions
Interventions
- BG-C9074 Drug
- Bevacizumab Drug
- Tislelizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 11, 2024
- Primary completion
- Sep 27, 2027
- Completion
- May 14, 2028
- Last update posted
- Apr 14, 2026
2024 – 2028
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Usc Norris Comprehensive Cancer Center (Nccc) | Los Angeles | California | 90089-1019 | Recruiting |
| University of Colorado Cancer Center | Aurora | Colorado | 80045-2517 | Recruiting |
| Florida Cancer Specialist Research Institute Lake Nona | Orlando | Florida | 32827-7400 | Recruiting |
| Sidney Kimmel Comprehensive Cancer At Johns Hopkins | Baltimore | Maryland | 21287 | Recruiting |
| James Cancer Hospital and Solove Research Institute | Columbus | Ohio | 43210-1240 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06233942, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06233942 live on ClinicalTrials.gov.